This supplement has been published in two parts. Part 2 is available at http://arthritis-research.com/supplements/15/S1.
Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
Anti-CD20 therapy using rituximab directly targeting B cells has been approved for treatment of non-Hodgkin lymphoma, rheumatoid arthritis and anti-neutrophil cytoplasmic antibody-associated vasculitides and h...